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Abstract
Background: Amoxicillin is an oral semi-synthetic, β-lactam antibiotic used to treat bacterial infections caused
by susceptible micro organisms. It is usually prepared in capsule, tablet and powder for oral suspension form.
Solid dosage forms for oral administration pose bioavailability problems related to the absorption process
The World Health Organization (WHO) has promoted the use of  generic brands in order to make the cost
of medicines affordable. Generic substitution could be considered when a generic copy of a reference drug
contains identical amounts of  the same active ingredient in the same dose formulation and route of  administration.
However, the presences of generic products those are not interchangeable with that of the innovator and/or
with each others have been reported.
Objective: To evaluate and compare the in-vitro dissolution profiles of  different generic brands of  amoxicillin
capsules with the innovator that are available in Ethiopian market.
Methods: Dissolution profiles for nine brands of amoxicillin capsules contained amoxicillin 500 mg which
are available in Ethiopian market were determined using a method from the United States Pharmacopoeia
(USP, 2009). The obtained dissolution profile data of  the eight brands were evaluated and compared with the
innovator brand (AmoxilTM) using two different statistical methods: the fit factors (f1 & f2) and the dissolution
efficiency (D.E.) model. Most generic brands of  amoxicillin capsules (62.5% of  the tested brands) are not
interchangeable with the innovator brand.
Results: The calculated f1 factor for Brand A and Brand G are 10.1 and 1.1 respectively. However, for the
rest six brands the f1 factors are greater than 15. The f2 factor for Brand G is 74.1 and for Brand A is 48.5
which is near to 50. Similarly, the f2 factors for the six brands are less than 50 which support the result of  the
f1 factors for the dissimilarity of these brands with the innovator brand. The mean dissolution efficiencies as
well as the 95% confidence intervals are within ±10% only for two brands, Brand F and Brand G.
Conclusion: Most generic brands of amoxicillin capsules (62.5%) are not interchangeable with the innovator
brand (AmoxilTM).
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Amoxicillin is an oral semi-synthetic, β-lactam
antibiotic used to treat bacterial infections caused by
susceptible micro organisms1. It is usually the drug
of choice within the class because it is better
absorbed, following oral administration, than other
β-lactam antibiotics. Amoxicillin is susceptible to
degradation by β-lactamase producing bacteria, and
so may be given with clavulanic acid to decrease its
susceptibility. Amoxicillin acts by inhibiting the
synthesis of  bacterial cell walls. It inhibits cross-
linkage between the linear peptidoglycan polymer
chains that make up a major component of the cell
wall of gram-positive bacteria2 .
Solid dosage forms for oral administration
are widely prescribed in clinical practice because they
are practical, stable, economical, and usually safe. On
the other hand, they pose bioavailability problems
related to the absorption process. Drug absorption
from a solid dosage form after oral administration
depends on the release of the drug substance from
the drug product, the solubilization of the drug under
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physiological conditions, and the permeability across
the gastrointestinal tract. For that reason, the
importance of dissolution tests and dissolution
profile for the establishment of  pharmaceutical
equivalence must be highlighted3, 4.
The World Health Organization (WHO) has
advocated the use of generic brands in order to make
the cost of medicines affordable especially for the
developing countries5. However, this approach has
not provided sufficient evidence for the substitution
of  one brand for another. In Ethiopia, the cost of  a
branded medicine may be as high as ten folds of
the generic medicine. To become confident in
substitution of branded with generics for
affordability and at the same time to achieve
therapeutic efficacy, bioequivalence studies become
fundamental6.
Generic substitution could be considered
when a generic copy of a reference drug contains
identical amounts of the same active ingredient in
the same dose formulation and route of
administration as well as meet standards for strength,
purity, quality and identity7. However different
reported studies over the last years revealed that
marketed products with the same amount of active
ingredient exhibit marked differences in their
therapeutic responses. The presences of  generic
products that are not interchangeable with that of
the innovator and/or with each others have been
reported 4, 6, 8-10.
The study was set up to evaluate and
compare the in-vitro dissolution profiles of different
generic brands of amoxicillin capsules with the









Figure 1:    Chemical structure of amoxicillin
Methods
Materials and equipments
Amoxicillin USP reference standard (potency =
864µg mg-1), Nine brands of amoxicillin capsules as
shown in table 1, dissolution test apparatus (PTW
II, Pharma Test, Germany), UV-Visible
spectrophotometer (Shimadzu, Japan) distilled water
and Microsoft excel to treat data statistically were
used.
Standard preparation
Stock standard solution (1 mg mL_1) was prepared
by dissolving 100 mg equivalent of anhydrous
amoxicillin USP reference standard in 100 mL of
distilled water. Six different concentration levels of
calibration solutions (0.01 to 1 mg mL_1)   were freshly
prepared by diluting suitable volumes of the stock
standard solution in appropriate volumetric flasks.
Table 1:   Samples of  amoxicillin capsules
Samples code Country of  origin Mfg date Exp date
AmoxilTM United Kingdom 06/2009 06/2014
A India 09/2009 08/2012
B India 10/2009 09/2012
C Cyprus 07/2009 07/2014
D Ethiopia 03/2010 03/2014
E India 08/2009 07/2012
F Ethiopia 11/2009 11/2014
G India 03/2009 02/2013
H India 12/2009 11/2011
The label claim for all samples is amoxicillin 500 mg
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Dissolution test and sample preparation
One capsule was placed in each of the six vessels of
the dissolution apparatus contained 900 ml of water
which were previously heated and maintained at 37
± 0.5 oC. 5 mL of sample was withdrawn from
each vessel after 5, 10, 20, 30, 40, 60 and 70 minutes.
After each withdrawal, an equal volume of water
that had been maintained at the same temperature
was replaced in order to maintain the total volume
of the medium constant. 2 mL of the sample
solution was quantitatively taken in to 10 mL
volumetric flask after being filtered through whatman
filter paper and diluted to volume with distilled
water. Absorbance of  the solution was measured at
272 nm.  Employed conditions for the dissolution
test have been shown in table 2.
Table 2: Dissolution test conditions for
amoxicillin capsule as per USP (2009)
Medium Water, 900 mL
Apparatus type II
Stirring rate 75 rpm
Detection Absorbance at 272 nm
Statistical methods
Fit factors
Fit factors or similarity indices are defined as follows:
Where Rt is the percentage of dissolved product
for a reference batch at time point t, Tt is the
percentage of dissolved product for the test batch,
n is the number of  time points. For each brand, the
calculations were made on the mean values for the
six vessels. The factor, f1, is the average % difference
over all time points in the amount of test brand
dissolved as compared to the reference brand. The
f1 value is 0 when the test and the reference profiles
are identical and increases proportionally with the
dissimilarity between the two profiles. The f2 value
is between 0 and 100. The value is 100 when the test
and the reference profiles are identical and
approaches zero as the dissimilarity increases 6, 11, 12 .
and
Dissolution efficiency
This concept is defined as follows:
Where, y is the percentage of dissolved product.
 D.E. is the area under the dissolution curve between
time points t1 and t2 expressed as a percentage of
the curve at maximum dissolution, y100, over the
same time period. For a capsule product, t1 can be
set to the period corresponding to disintegration of
the capsule shell. The integral of the numerator, i.e.
the area under the curve is calculated by a model
independent method, the trapezoidal one. The area




 is the i th time point, y
i 
is the percentage of




Disintegration could be directly related to dissolution
and subsequently to bioavailability of  a drug. A drug
filled in a capsule shell is released rapidly as the capsule
shell disintegrates; a fundamental step for immediate
release dosage forms because the rate of
disintegration affects the dissolution and afterward
the therapeutic efficacy of  the medicine. For
comparison of dissolution profiles with dissolution
efficiency model, the lag phase should be
determined12. And hence, disintegration test was
carried out as per USP, 2009 prior to the actual
dissolution test and 90% of the studied brands have
been averagely disintegrated within ten minutes.
Summarized disintegration test results have been
presented in table 3.
In the presented study, sample quantification
was based on the previously constructed calibration
curve. The calibration curve has correlation
coefficient (r) and linear equation of 0.9994 and Y
= 2.9001 X + 0.0336 respectively. It is linear in the
ranges of 0.01 – 1.00 mg mL-1.
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Table 3:   Summarized disintegration test results
for the tested brands of amoxicillin.
Tested brands Disintegration times ( min :
second)
Minimum   Maximum  Average
AmoxilTM 5:34 6:16 5:50
A 3:40             5:48             4:18
B 5:07 7:45 6:22
C 4:43 6:39 5:33
D 4:32 6:24 5:19
E 3:37 4:49 4:14
F 3:41 8:13 5:40
G 7:06             13:00           11:14
H 3:11 4:47 3:51
The dissolution test according to USP 2009 requires
that each unit not less than Q + 5% of the active
ingredient should dissolve with in 60 minutes for
the first six units (stage 1). But, if the requirement at
stage 1 is not met, another six units will be tested
and the mean percent dissolved for the twelve units
is not less than Q% and no unit is less than Q – 15%
(stage 2). In this study all the tested brands have
satisfied these requirements and thus were in
agreement with the USP 2009 specifications.
However, six of the nine tested products have
satisfied these requirements after passing stage 2 test.
Dissolution test results have been presented in table
4.
Table 4: Dissolution results of  the tested brands of  amoxicillin at USP 2009, Test 1 sampling
time (60 minutes)
%dissolved
Amoxil TM A B C D E F G H
Stage 1
Min 94.4 85.7 80.3 83.1 77.8 69.9 78.9 93.8 75.5
Max 98.6 96.7 86.5 87.6 86.5 82.9 87.9 99.5 87.9
Mean (n=6) 96.5 91.1 81.3 84.0 80.4 76.7 81.5 95.1 81.0
Stage 2
Min 76.1 77.8 78.3 75.5 74.7 78.6
Max 89.1 89.1 87.9 84.3 89.1 86.2
Mean(n=12) 82.1 84.5 83.8 80.0 82.5 81.2
The dissolution profiles of the innovator product
as well as the tested generic products have been
presented in figure 2. According to the result, the
innovator product and Brand G have shown
superior dissolution performances over the rest of
the tested generic products.
The percentage dissolved was tested
statistically in order to compare the dissolution
profiles of the tested eight brands of amoxicillin
capsules with the innovator. In this study the two
most important and widely engaged methods have
been used: the fit factors and dissolution efficiency
(D.E.).
The dissolution data with the result obtained
from the calculation of the fit factors has been shown
in table 5. Similarly, table 6 shows the calculated
dissolution efficiencies with their respected 95%
confidence intervals.
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Figure 2:    Dissolution profiles of nine brands of amoxicillin capsule
Table 5:   Dissolution data for the calculation of  f1 and f2
Time
(min)
% mean dissolved  ± SDa
AmoxilTM A B C D E F G H
5 44.0± 7.2 26.3± 7.4 21.6±7.2 18.4± 6.8 24.6± 6.9 19.0±4.5 36.2± 3.4 26.2± 11.5 29.7± 3.7
10 67.0± 9.7 46.7±3.2 35.6± 7.9 39.2± 6.4 44.5± 9.7 30.6±4.6 49.3± 5.4 60.4± 11.3 41.1± 5.5
20 79.7± 5.6 64.3± 7.0 55.6± 6.8 54.5± 3.9 56.5± 5.3 46.4± 5.1 60.6± 2.9 82.3± 7.1 51± 13.5
40 88.7± 3.3 86.8± 9.5 71.7± 3.9 74.2± 2.4 69.4± 4.6 68.1±7.6 73.2± 3.1 90.9± 4.9 69.1± 6.3
60 96.5± 2.0 91.1±4.3 81.3± 2.6 84± 1.6 80.4± 4.1 76.7± 5.2 81.5± 3.2 95.1± 2.1 77.9± 5.3

















aSD: standard deviation  f1: the difference factor         f2: the similarity factor
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Table 6:    Dissolution efficiencies with 95%
confidence intervals
Tested brands Mean D.E(%)     D.E     CIS
                         with CIS
AmoxilTM 88.9  (86.9, 90.8) 0.0 0
A 80.1 (75.1, 85.1) 8.8        15.7
B 80.2 (76.4, 84.0) 8.7          4.4
C 77.1 (74.3, 79.9) 11.8        16.5
D 81.0 (77.8, 84.2) 7.9         13.0
E 75.8 (73.1, 78.6) 13.1       17.7
F 85.0 (83.6, 86.3) 3.9          7.2
G 90.2 (87.6, 92.7) 1.3          3.2
H 79.0 (75.9, 82.2) 9.9         14.9
D.E: Dissolution Efficiency
CIS: Confidence Intervals
“ D.E = Innovator – test brand “CIS is calculated
by considering the maximum possible mean
D.E. value of  Innovator and minimum possible
mean
D.E. value of  other brands.
Discussion
In the literature, different methods which can be used
to compare dissolution profiles data have been
reported3, 4, 11-14. However, in this study the two most
important and widely engaged methods have been
used: the fit factors and dissolution efficiency (D.E.).
The fit factors can be expressed by two approaches:
f1 (the difference factor) and f2 (the similarity factor).
Two dissolution profiles to be considered similar
and bioequivalent, f1 should be between 0 and 15
whereas f2 should be between 50 and 1006 .
In the calculations of fit factors and
dissolution efficiency values, the mean percent
dissolved at 5 minutes was excluded for the
disintegration of the capsule shell had not been
completed at this point of time. Therefore, as shown
in table 5, the dissolution profiles of all brands except
Brand G are not similar with the innovator brand
(AmoxilTM) using the f2 factor. But, using the f1
factor besides to Brand G, Brand A can probably
be considered as bioequivalent with the innovator
brand.
The second comparison method employed
in this study was dissolution efficiency (D.E.) model.
The calculations were made for each individual vessel.
Thus, the mean D.E. for each brand with its 95%
confidence intervals was obtained and compared
by measuring the difference between the mean D.E.
and confidence intervals of  the innovator brand and
the test brands. If  the differences of  the mean
dissolution efficiencies as well as the 95% confidence
intervals are within appropriate limits (±10%), one
can conclude that the reference and test dissolution
profiles are equivalent12. As shown in table 6, both
conditions have been satisfied only for two brands,
Brand F and Brand G. Therefore, the dissolution
profiles of Brand G and Brand F are similar with
each other and with the innovator as per this method.
            The calculation of f1 and f2 is very simple
but the calculation for D.E. is more complex. Fit
factors comparison (f1 and f2) do not reveal the intra-
batch variability because the calculations need to be
made on the mean. Moreover, it is also said to be
insensitive to the shapes of dissolution profiles and
does not put into consideration unequal spacing
between sampling time points.  Even though f2 is
quite closely correlated with D.E. it is more difficult
to interpret f2 than D.E. data without reference to
dissolution data or curves, since it relates to
differences between curves, and because of  its non-
linear behaviour12 .
           In this study, all the comparison methods
have proven the similarity of the dissolution profile
of  only Brand G with the innovator. The f1 factor
and the D.E. independent model have included
Brand A and F respectively in addition to Brand G.
In f2 comparison method, these generic brands are
also aspirant, have closest value to 50 in particular
Brand A. Similarly, in f1 comparison Brand F was
the next brand with closest value to 15. In D.E. model,
Brand A is slightly excluded due to the increment of
the difference of  the confidence intervals. Even
though all the tested products have passed the USP
(2009) specifications, most of the generic products
are not interchangeable with the innovator product.
The three brands: Brand A, Brand F and Brand G
may probably interchangeable with each other and
with the innovator brand (AmoxilTM). However the
rest five brands may not probably interchangeable
with the innovator brand.
Limitations of the study
The content of the active ingredient of each tested
product is not assessed against the label claim.
Moreover; in-vitro dissolution test might be an
indicator to investigate the interchangeability of
products. The study has not been assisted by other
methods like in-vivo bioequivalence study for better
conclusion.
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Conclusion
Most generic brands of amoxicillin capsules (62.5%)
are not interchangeable with the innovator brand
(AmoxilTM).
Recommendations
Overall, it can be recommended that drug regulatory
Authorities should be reinforced and capacitated in
order to address proper post marketing surveillance
for sensitive medicines like antibiotics. Any drug
regulatory authorities should also stick to the
requirement of bioequivalence studies during market
authorization. Further studies shall be done on the
tested products for better conclusion of the
interchangeability of the generic products with the
innovator. The samples need to be assessed in terms
of  dosage uniformity, water content and assay.
Moreover, in-vivo bioequivalence study on the
generic products is highly considerable.
References
1. Abrue L, Ortiz R, Castro S, Pedrazzoli, J. HPLC
determination of  amoxicillin comparative
bioavailability in healthy volunteers after a single
dose administration. J. Pharm. Sci., 2003; 6(2):
223 – 230.
2. Ashanagar A, Naseri N. Analysis of  Three
Penicillin Antibiotics (Ampicillin, Amoxicillin
and Cloxacillin) of Several Iranian
Pharmaceutical Companies by HPLC. E.
Journal of  chemistry 2007; 4:536 – 545.
3. Fernandes C, Junqueira RG, Campos L, Pianetti
GA. Dissolution test for lamivudine tablets:
Optimization and statistical analysis. Journal of
Pharmaceutical and Biomedical Analysis 2006 ; 42:
601–606.
4. Ferraz HG, Carpentieri LN, Watanabe SP.
Dissolution Profile Evaluation of Solid
Pharmaceutical Forms Containing
Chloramphenicol Marketed in Brazil. Brazilian
archives of  biology and technology 2007;  50: 57 –
65.
5. WHO (2004). World Health Organization
medicines strategy; countries at the core 2004-
2007, p 68. Available at http://libdoc.who.int/
hq/ 2004/WHO
6. Ngwuluka NC, Lawal K, Olorunfemi PO,
Ochekpe NA. Post-market in vitro
bioequivalence study of six brands of
ciprofloxacin tablets/caplets in Jos, Nigeria.
Scientific Research and Essay, 2009;  4 (4): 298-
305.
7. Meredith P. Bioequivalence and other
unresolved issues in generic drug substitution.
Clinical Therapeutics, 2003; 25 (11): 2875-2890.
8. El-Sayed  A, Boraie NA, Ismail FA, El-
Khordagui LK, Khalil SA. Assessment of the
pharmaceutical quality of  omeprazole capsule
brands marketed in Egypt. Eastern Mediterranean
Health Journal, 2007;13 (6): 1427 – 1437.
9. Ghafari S, Esmaeili S, Aref  H, Naghibi F,
Mosaddegh M. Qualitative and Quantitative
Analysis of  Some Brands of  Valerian
Pharmaceutical Products. Ethno-med 2009; 3(1):
61 – 64.
10. Hamdan II, Jaber AKB. Pharmaceutical
Evaluation of  Metformin HCl Products
Available in the Jordanian Market. Jordan Journal
of Pharmaceutical Sciences 2010; 3(1): 1 - 6.
11. Polli JE, Rekhi GS, Augsburger LL, Shah VP.
Methods to Compare Dissolution Profiles and
a Rationale for Wide Dissolution Specifications
for Metoprolol tartarate Tablets. Journal of
Pharmaceutical Sciences, 1997; 86(6): 690 – 700.
12. Anderson NH, Bauer M,  Boussac N, Khan-
Malek R, Munden P, Sardaro S. An evaluation
of fit factors and dissolution efficiency for the
comparison of  in vitro dissolution profiles.
Journal of  Pharmaceutical and Biomedical Analysis
1999; 17: 811 – 822
13. USP (2009) USP 31 D NF 26. The United
States Pharmacopeial Convention, Inc.,
Rockville, MD, USA.
14. Mi-chia Ma, Ru-pyng Lin, Jen-pei Liu. Statistical
evaluation of dissolution similarity. Statistica
Sinica, 1999; 9: 1011-1027.
